Market Overview

Morgan Stanley Sees Johnson & Johnson Taking Rx Estimates Higher

Related JNJ
Riding The Bull Market With These 2 Momentum ETFs
What Johnson & Johnson's 'Chart Watchers' Need To Know
Making Money With Charles Payne: 11/19/14 (Fox Business)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Johnson & Johnson (NYSE: JNJ).

In the report, Morgan Stanley noted, “We're adjusting our pharma estimates modestly to reflect our changing market views and July sales and prescriptions data from IMS. Overall. we're taking our 2016 pharma sales estimates up by 3%, driving a 2% revision in EPS. The largest swing factors include Imbruvica and Invokana.”

Johnson & Johnson closed on Friday at $103.73.

Latest Ratings for JNJ

DateFirmActionFromTo
Oct 2014Guggenheim SecuritiesInitiates Coverage onNeutral
Oct 2014BernsteinDowngradesMarket Perform
Aug 2014JefferiesMaintainsHold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (JNJ)

Around the Web, We're Loving...

Get Benzinga's Newsletters